TRT and Cholesterol — How Does Testosterone Affect Your Lipid Profile?
Testosterone therapy usually lowers total cholesterol and LDL slightly, but it often lowers HDL too — which historically raised concern. We explain why these changes rarely translate into a real worsening of cardiovascular risk, and how to read a lipid panel in the context of TRT.
Number of studies
3
Safety
Requires caution
Time to effects
Most changes in the lipid profile stabilize within the first 3–6 months of therapy; further significant shifts after that point are less typical with stable dosing.
Who it's for
Table of contents
TL;DR
Testosterone therapy usually lowers total cholesterol and LDL slightly, but it often lowers HDL too — which historically raised concern. We explain why these changes rarely translate into a real worsening of cardiovascular risk, and how to read a lipid panel in the context of TRT.
- →Understanding the mechanism helps you avoid panicking over a small HDL drop during TRT
- →Enables an informed distinction between lipid changes that are clinically meaningful and those with little prognostic weight
- →Makes it easier to discuss the full picture of cardiovascular risk with a doctor, rather than fixating on a single result
| Type of phenomenon | A physiological side effect of therapy, not a standalone intervention |
|---|---|
| Level of evidence | Moderate — consistent observational and RCT data, including one large trial with hard endpoints |
| Total cholesterol and LDL | Usually a slight drop under TRT |
| HDL | Often a slight drop, dependent on dose and delivery route |
| Triglycerides | Often improve, especially with coexisting metabolic syndrome |
| Effect on hard cardiovascular endpoints | No confirmed increase in risk in the TRAVERSE trial despite lipid changes |
| Recommended monitoring | A fasting lipid panel before TRT and periodically during treatment, as part of a broader risk assessment |
Understand
Overview
A lipid panel is one of the standard tests run both before starting testosterone therapy and during it. TRT's effect on the lipid profile is real and fairly well documented, but also more nuanced than the oversimplified slogans circulating online — "testosterone lowers cholesterol" on one side, or the opposite, "testosterone destroys HDL and kills your heart." The truth is more measured and depends on which lipid parameter you're looking at.
The most consistently observed effect is a small drop in total cholesterol and LDL — usually in the range of a few to just over ten percent, more pronounced in men who had low baseline testosterone and elevated lipids before treatment. The second, more common and historically more controversial effect is a drop in HDL, the so-called "good cholesterol." Since low HDL is generally regarded as a marker of increased cardiovascular risk, this TRT effect was for years interpreted as potentially concerning. The third piece of the puzzle is triglycerides, which improve in some patients — partly independent of testosterone itself, and partly as a side effect of the body composition changes TRT typically brings (a drop in visceral fat, a rise in muscle mass, improved insulin sensitivity).
The key question isn't "does TRT change the lipid panel" — because it does, fairly consistently across studies — but "do those changes, and the HDL drop in particular, actually translate into higher risk of a heart attack or stroke." The answer given by the best available data, including the large randomized TRAVERSE trial, is surprisingly reassuring: despite a slight drop in HDL observed in the testosterone group, the rate of major cardiovascular events wasn't higher than in the placebo group. That's one of the stronger arguments for not treating a single, isolated lipid panel change as a standalone red flag, but as one of many elements in a full cardiovascular risk assessment.
It's also worth stressing that the size and direction of lipid changes under TRT depend on the delivery form. Historical data showing large, unfavorable HDL drops come largely from studies of oral 17-alpha-alkylated androgens (e.g. methyltestosterone) — compounds with a significant first-pass liver effect that haven't been a standard part of modern replacement therapy for a long time. The forms used today — intramuscular or subcutaneous injections, transdermal gels and patches, subcutaneous implants, and the newer generation of oral preparations absorbed while bypassing the portal circulation — cause much smaller and usually clinically minor shifts in the lipid panel.
Mechanism of action
Testosterone affects lipoprotein metabolism on several levels at once, and the net effect on the lipid panel is the sum of these interactions, some of which pull in opposite directions. The best-documented mechanism is androgens' effect on hepatic lipase activity — an enzyme responsible for the catabolism of HDL lipoproteins. Testosterone increases this enzyme's activity, which speeds the breakdown of HDL particles and explains the drop in this fraction most commonly seen in studies. This effect is dose- and route-dependent — stronger at high doses and with forms that involve significant first-pass liver metabolism, weaker with physiological parenteral dosing.
In parallel, testosterone affects hepatic LDL receptors, increasing their expression and thereby speeding the clearance of LDL particles from circulation — one of the proposed mechanisms behind the observed drop in LDL and total cholesterol. Androgens also modulate the activity of CETP (cholesteryl ester transfer protein), which mediates the exchange of cholesteryl esters and triglycerides between lipoproteins, further shaping the final distribution of lipid fractions.
A third mechanism is indirect and stems from the body composition changes TRT typically produces in men with hypogonadism: a reduction in body fat, especially visceral fat, a rise in lean muscle mass, and improved tissue insulin sensitivity. Visceral fat is metabolically active and strongly tied to elevated triglycerides and insulin resistance — reducing it, independent of testosterone's direct effect on the liver, itself favors an improved triglyceride profile. This partly explains why TRT's effect on triglycerides tends to be more favorable and more consistent in men with metabolic syndrome or type 2 diabetes than in metabolically healthy men.
It's worth separating these physiological mechanisms from the question of their clinical significance. A drop in HDL of a few percentage points, driven by increased hepatic lipase activity, doesn't necessarily carry the same prognostic weight as low HDL resulting from, say, obesity, diabetes, or a sedentary lifestyle — the metabolic context in which a given parameter changes matters for interpreting its impact on actual cardiovascular risk. That's exactly why data from large randomized trials assessing hard endpoints (heart attacks, strokes, cardiovascular deaths), rather than lipid values alone, matter so much for correctly interpreting this phenomenon.
Rise in hepatic lipase activity
Testosterone increases the activity of the enzyme responsible for HDL catabolism, speeding the breakdown of this fraction and explaining the most commonly observed drop in its concentration.
Increased LDL receptor expression
Androgens boost hepatic uptake of LDL particles, favoring a drop in LDL and total blood cholesterol.
Modulation of CETP and lipid exchange between lipoproteins
Testosterone affects the protein that transports cholesteryl esters, changing how lipids are distributed among the various fractions.
Indirect effect via body composition change
Reduced visceral fat and improved insulin sensitivity, typical of effective TRT, independently favor lower triglycerides.
Evidence: moderate — based on 3 studies in this database.
Benefits
Common myths
MythTRT always worsens cholesterol and increases the risk of a heart attack.
FactTotal cholesterol and LDL usually drop slightly under TRT, and the largest available trial with hard endpoints (TRAVERSE) found no increased risk of major cardiovascular events despite the lipid changes observed.
MythAny drop in HDL during TRT is an alarm signal requiring immediate discontinuation.
FactThe HDL drop tied to TRT largely results from increased hepatic lipase activity, and its prognostic weight in this specific context isn't the same as low HDL resulting from, say, obesity — the decision should be based on the full risk picture, not a single parameter.
MythSince testosterone affects lipids, the lipid panel needs to be checked monthly.
FactStandard practice is a check at 3–6 months from the start of therapy, then every 6–12 months on stable dosing — more frequent testing rarely provides additional, clinically meaningful information.
Forms & variants
TRT and Cholesterol — How Does Testosterone Affect Your Lipid Profile? comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Intramuscular or subcutaneous injections (e.g. testosterone enanthate, cypionate)
Bypasses first-pass liver metabolism with parenteral administration; a documented, usually moderate effect on the lipid panel, more strongly tied to peak testosterone concentrations after injection.
Best for: The most commonly used TRT form; requires standard lipid monitoring at typical intervals
Transdermal gels and patches
More stable testosterone concentrations across the day, bypassing first-pass hepatic metabolism; data generally suggest a milder effect on lipid fractions than the peak doses seen after injection.
Best for: Patients with an unfavorable baseline lipid profile, or who prefer a more stable hormonal profile
Modern oral preparations (testosterone undecanoate absorbed while bypassing the portal circulation)
Unlike older 17-alpha-alkylated androgens, modern oral forms are absorbed mainly via the lymphatic route with limited first-pass liver metabolism, which reduces their historically documented, strongly unfavorable effect on HDL.
Best for: Patients who prefer an oral form but still need regular lipid panel monitoring
Check your profile
Not sure which supplements actually make sense for you?
Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
Total cholesterol and LDL usually drop slightly. HDL, on the other hand, often drops — the most commonly observed and historically most debated lipid effect of TRT. Triglycerides usually improve, especially in men with metabolic disturbances.
Not directly or reliably. The large TRAVERSE trial, covering more than 5,000 men with hypogonadism and existing or high cardiovascular risk, found no increased rate of heart attacks, strokes, or cardiovascular deaths in the testosterone-treated group despite the observed HDL drop. An isolated change in this parameter should be interpreted in the context of a full risk assessment, not on its own.
Typically before starting therapy, again at 3–6 months, then every 6–12 months on stable dosing with no concerning results — following the standard testosterone therapy monitoring schedule.
Yes. Modern parenteral forms (injections, gels, patches) and newer-generation oral preparations absorbed while bypassing the liver usually cause smaller lipid changes than older oral 17-alpha-alkylated androgens, which placed significant strain on the liver and lowered HDL more noticeably.
Not automatically. The decision is made by the physician based on the full picture — including blood pressure, glucose, family history of cardiovascular disease, and how values trend over time — rather than a single, isolated lipid panel result.
Yes, statins and other lipid-lowering drugs can be used alongside TRT without significant pharmacokinetic interactions, and their LDL-lowering effectiveness stays independent of testosterone therapy.
Dosage & timing
Typical dose
A fasting lipid panel before starting TRT, then a check at 3–6 months from the start of treatment, and after that usually once every 6–12 months on stable therapy
Form
A blood draw after a 9–12 hour fast: total cholesterol, LDL, HDL, triglycerides
A single abnormal result, especially an isolated HDL drop, shouldn't on its own be grounds to stop therapy without assessing the full cardiovascular risk picture, including blood pressure, glucose, body weight, and family history.
Best times to take it
- First fasting lipid panel before starting TRT, as a baseline reference
- A check at 3–6 months from the start of treatment, by when most lipid changes have already stabilized
- Further checks every 6–12 months with stable dosing and no concerning symptoms
What actually helps
Standard lipid panel monitoring during TRT
Moderate evidenceRegular checks of total cholesterol, LDL, HDL, and triglycerides as part of routine oversight of therapy, alongside CBC, PSA, and hematocrit.
Choosing a delivery form with a smaller hepatic impact
Moderate evidenceIn patients with an unfavorable baseline lipid profile, favoring parenteral forms (injections, gels, patches) over older oral preparations with significant first-pass metabolism.
Lifestyle intervention alongside TRT
Strong evidenceStrength and aerobic training, visceral fat reduction, and diet support improvements in triglycerides and LDL independent of testosterone itself, reinforcing therapy's favorable effects.
Assessing full cardiovascular risk rather than a single parameter
Moderate evidenceInterpreting lipid changes together with blood pressure, glucose, family history, and other markers, rather than reacting solely to an isolated HDL drop.
Safety
Side effects & contraindications
Possible side effects
Drop in HDL — usually by a few to just over ten percent, more pronounced at higher doses and with forms involving more hepatic metabolism
Less commonly: no meaningful change or a slight rise in HDL, especially in men with very low baseline testosterone and metabolic disturbances
Occasionally observed lack of LDL improvement despite a drop in total cholesterol — needs interpreting alongside the full lipid profile
The lipid effect isn't uniform across the population — some men see no meaningful change in any fraction
Contraindications
Not directly applicable — this describes a phenomenon accompanying therapy, not a standalone intervention requiring its own contraindications
A very unfavorable baseline lipid profile or documented cardiovascular disease doesn't automatically rule out TRT, but calls for closer monitoring and an individual risk assessment by the treating physician
Interactions
Statins and other lipid-lowering drugs — can be used alongside TRT without significant pharmacokinetic interactions; their LDL-lowering effectiveness isn't blunted by testosterone
Fibrates — no documented significant interactions with TRT, but combined treatment calls for standard monitoring of lipid profile and liver function
Drugs affecting the liver (e.g. certain antifungals, chronic heavy alcohol use) — can intensify the hepatic component of TRT-related lipid changes, especially with oral forms
Is it worth taking?
Who it's for
- Men starting or continuing TRT who want to know what to expect on a follow-up lipid panel
- Patients concerned about an HDL drop found on blood work done during therapy
- People with metabolic syndrome or type 2 diabetes considering TRT and asking about its effect on triglycerides
- Doctors and patients who want to interpret lipid changes in the context of overall cardiovascular risk, rather than in isolation
Not for
- Not directly applicable — this describes a phenomenon accompanying therapy, not a standalone intervention requiring its own contraindications
- A very unfavorable baseline lipid profile or documented cardiovascular disease doesn't automatically rule out TRT, but calls for closer monitoring and an individual risk assessment by the treating physician
Evidence
Worth knowing
Total cholesterol and LDL usually drop slightly under TRT, more so in men with low baseline testosterone.
HDL often drops slightly, mainly due to increased hepatic lipase activity.
Triglycerides often improve, especially alongside a drop in visceral fat.
The TRAVERSE trial (over 5,000 men, up to 33 months of follow-up) found no increased risk of heart attack, stroke, or cardiovascular death in the testosterone group despite lipid changes.
Historical, strongly unfavorable HDL data come mainly from older oral 17-alpha-alkylated androgens, rarely used in modern TRT.
Studies
Despite a slight drop in HDL observed in the testosterone group, the rate of major cardiovascular events after more than two years of follow-up didn't differ significantly from the placebo group.
Lincoff A.M. et al. (TRAVERSE trial), New England Journal of Medicine, 2023
Cardiovascular Safety of Testosterone-Replacement Therapy
Strong evidenceLincoff AM, Bhasin S, Flevaris P et al. (TRAVERSE trial) · New England Journal of Medicine · 2023
A large randomized trial involving more than 5,200 men with hypogonadism and existing or high cardiovascular risk. Despite a slight HDL drop in the testosterone group, the rate of major cardiovascular events after an average of 22 months of follow-up didn't differ significantly from placebo — key context for interpreting TRT-related lipid changes.
View studyEffects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis
Moderate evidenceIsidori AM, Giannetta E, Greco EA et al. · Clinical Endocrinology · 2005
A meta-analysis of randomized trials showing a slight drop in total cholesterol under testosterone therapy, more pronounced in men with lower baseline hormone levels, with no significant change in LDL across the pooled studies.
View studyAdverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis
Moderate evidenceHudson J, Cruickshank M, Quinton R et al. · The Lancet Healthy Longevity · 2022
An individual patient data meta-analysis of more than 3,000 participants from randomized trials, showing a moderate drop in total cholesterol, HDL, and triglycerides in testosterone-treated groups, without demonstrating increased cardiovascular event risk in short- and medium-term follow-up.
View studySources & bibliography
- Lincoff et al. 2023 — TRAVERSE, New England Journal of Medicine
- Isidori et al. 2005 — meta-analysis, Clinical Endocrinology
- Hudson et al. 2022 — IPD meta-analysis, The Lancet Healthy Longevity
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Piotr ZielińskiEndocrinologist
Piotr has practiced endocrinology for more than fifteen years, mostly in male hormonal disorders and metabolic health. He joined VitMode as a scientific consultant because, as he jokes, he got tired of explaining the same testosterone questions at every appointment and decided to write the answers down properly, once. He reviews content on hormone therapy, supplement pharmacology and drug interactions, making sure articles never turn into encouragement to self-supplement in situations that genuinely need diagnostics and medical supervision. His professional motto — "evidence first, enthusiasm second" — has come up more than once with a patient who arrived with a supplement plan they found online.
268 publications on this site
Medical review
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna studied molecular biology at the University of Warsaw, then spent eight years after her PhD in a lab researching the mechanisms of cellular aging and autophagy. She stumbled into science journalism almost by accident — frustrated by how easily her field's findings get oversimplified in the media, she started a blog explaining the biology of aging in plain language. That blog became the seed of VitMode. Today Anna oversees the entire editorial process, holding every piece to the same rigor her old lab demanded: primary sources, methodology checks, and honesty about the limits of the evidence. Outside work, she's a dedicated boulderer.
196 publications on this site
Related entries
4.7TRT (Testosterone Replacement Therapy) — What Is It and Who Is It For?
TRT isn't a supplement for fatigue — it's pharmacological treatment for a confirmed testosterone deficiency, with a real but limited list of benefits and an equally real list of people who simply don't qualify for it.
4.6Lipid Panel
The lipid panel is one of the most important — and still one of the most frequently misread — preventive blood tests: 'total cholesterol' alone tells you less than the ratios between its fractions.
4.7TRT — Side Effects and Therapy Monitoring
Erythrocytosis, fertility impact, PSA screening, and the cardiovascular risk question — what testosterone replacement therapy safety actually involves and how it's monitored.
4.5Can Testosterone Affect Cholesterol?
Long before anyone starts TRT, natural testosterone level correlates with lipid profile in population studies — lower testosterone is linked to higher triglycerides and lower HDL. We explain this broader, epidemiological relationship and why it shouldn't be confused with the specific effect of testosterone therapy itself.
4.7What Tests Are Needed Before TRT? The Complete Pre-Treatment Testing List
Before a physician can qualify a patient for testosterone therapy, a far broader panel of tests is needed than testosterone level alone. The full list of blood tests, symptom questionnaires, and criteria that determine whether TRT is safe and appropriate.
4.7How Often to Test Testosterone on TRT? Monitoring Schedule and Checkups
Starting testosterone therapy isn't the end of diagnostics — it's the start of a new, recurring rhythm of checkups. We explain which tests happen at month 3, which at year one, and which need repeating for as long as therapy continues — and how the schedule differs between injectable and gel forms.
4.7TRT and Your Heart — Does Testosterone Therapy Raise Heart Attack Risk?
For a decade, testosterone therapy operated under the shadow of an FDA warning about heart attack risk. The large randomized TRAVERSE trial from 2023 finally gave a clear answer — though not as simple as the headlines suggested. We walk through the whole story, from controversial observational studies to where the evidence stands today.
Related articles
PoradnikiGarlic and LDL Cholesterol: Does It Really Lower It?
"Garlic lowers cholesterol" is one of the oldest folk health tips — and, rare for this category, partly confirmed by meta-analyses of clinical trials. But the devil is in the details: the effect is real (an LDL drop of about 9 mg/dL), yet it applies only to people with already elevated cholesterol, requires supplementation lasting more than 2 months, and has nothing to do with occasionally tossing a clove of garlic into dinner.
August 23, 2026
PoradnikiCinnamon and LDL Cholesterol: What Does the Meta-Analysis Actually Show?
Cinnamon is often marketed as a natural way to lower "bad" LDL cholesterol. A meta-analysis of 13 randomized trials involving 750 people, however, paints a more nuanced picture than the popular belief: cinnamon significantly lowers triglycerides and total cholesterol, but its effect on LDL specifically turned out to be statistically insignificant.
September 2, 2026
PoradnikiHow to Raise HDL Cholesterol? 8 Ways Backed by Real Evidence
HDL is often called "good cholesterol," and the internet is full of advice on raising it — from supplements to drastic diets. The problem is that some of these methods really do raise the HDL number on your bloodwork, yet don't translate into lower risk of heart attack or stroke. We check eight concrete, researched ways to raise HDL — and honestly flag which of them also have evidence for real clinical benefit, and which simply move a number.
September 7, 2026
PoradnikiTRT or Lifestyle Change? What Actually Raises Testosterone Before You Consider Therapy
Before considering testosterone replacement therapy, it's worth checking how much sleep, training, and fat loss can realistically achieve — and when these interventions genuinely aren't enough.
July 29, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.